1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Akero First To Show Benefit In Cirrhotic NASH Patients

 
• By Joseph Haas

Although the data are from a small cohort of an ongoing study, Akero’s FGF21 analog reduces fibrosis score by at least one stage in 33% of cirrhotic NASH patients.

3D illustration of many arrows symbols pointing in the same direction and one arrow going back. Concept of regression.
In a small sample, Akero's EFX showed an ability to reverse cirrhosis in NASH patients

Akero Therapeutics, Inc.’s Phase II FGF21 analog efruxifermin (EFX/AKR-001) demonstrated the ability to reduce fibrosis score by one stage or more in non-alcoholic steatohepatitis patients with cirrhosis after just 16 weeks of treatment, becoming the first NASH candidate to show a benefit in cirrhotic patients. The biotech noted on 22 March that the data derived from a 30-patient cohort of a Phase IIa study that was not powered to show statistical significance on histologic endpoints, but analysts called the data potentially groundbreaking all the same.

Previously, the South San Francisco-based company had shown that EFX could reduce hepatic fat by 63%-72% in NASH patients with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

 
• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

What Incyte Investors Expect From New CEO Bill Meury

 
• By Andrew McConaghie

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Bayer Buoyant After EU Nod For Twice-Yearly Eylea

 
• By Kevin Grogan

Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.

Veru’s Enobosarm Market Potential Enhanced By New Obesity Data

 
• By Aakash Babu

The late-stage biotech posted results from the maintenance extension portion of its Phase IIb QUALITY trial in which enobosarm reduced weight regain and helped preserve lean mass in patients who discontinued their semaglutide weight-loss treatment.

More from R&D

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

Pfizer’s Hympavzi Poised For Broader Hemophilia Label

 
• By Alaric DeArment

The drugmaker announced positive topline results for the drug in hemophilia A and B patients with inhibitors, on top of the existing approval for patients without inhibitors.

Pharma Growth And Biotech Squeeze Will Shape Sector To 2030, Evaluate Forecasts

 
• By Andrew McConaghie

Evaluate’s five-year forecast sees steady growth for big pharma despite recent political turmoil but tougher times ahead for the ‘have nots’ of biotech.